Z X Meng1, J Nie, J J Ling, J X Sun, Y X Zhu, L Gao, J H Lv, D Y Zhu, Y J Sun, X Han. 1. Key Laboratory of Human Functional Genomics of Jiangsu Province, Clinical Diabetes Centre of Jiangsu Province, Nanjing Medical University, Nanjing, People's Republic of China.
Abstract
AIMS/HYPOTHESIS: Liver X receptors (LXRs) are important transcriptional regulators of lipid homeostasis and proliferation in several cell types. However, the roles of LXRs in pancreatic beta cells have not been fully established. The aim of this study was to investigate the effects of LXRs on pancreatic beta cell proliferation. METHODS: Gene expression was analysed using real-time RT-PCR. Transient transfection and reporter gene assays were used to determine the transcriptional activity of LXRs in pancreatic beta cells. Cell viability and proliferation were analysed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DNA fluorometric, BrdU labelling and [(3)H]thymidine incorporation assays. Cell cycle distribution was investigated by flow cytometry analysis. Adenovirus-based RNA interference was used to knockdown LXRalpha, LXRbeta and p27 in MIN6 cells and mouse islets. RESULTS: We found that both Lxralpha (also known as Nr1h3) and Lxrbeta (also known as Nr1h2) were expressed and transactivated the LXR response element in HIT-T15 and MIN6 cells. Activation of LXRs dose-dependently inhibited pancreatic beta cell viability and proliferation. This was accompanied by beta cell cycle arrest at the G1 phase. Furthermore, LXR activation increased levels of the p27 protein by inhibiting its degradation. Knockdown of p27 reversed these effects of LXR activation on growth inhibition and cell cycle arrest. CONCLUSIONS/ INTERPRETATION: Our observations indicate that LXR activation inhibits pancreatic beta cell proliferation through cell cycle arrest. A well-known regulator of pancreatic beta cell cycle progression, p27, is upregulated and mediates the effects of LXRs on growth inhibition in beta cells. These observations suggest the involvement of aberrant activation of LXR in beta cell mass inadequacy, which is an important step in the development of type 2 diabetes.
AIMS/HYPOTHESIS: Liver X receptors (LXRs) are important transcriptional regulators of lipid homeostasis and proliferation in several cell types. However, the roles of LXRs in pancreatic beta cells have not been fully established. The aim of this study was to investigate the effects of LXRs on pancreatic beta cell proliferation. METHODS: Gene expression was analysed using real-time RT-PCR. Transient transfection and reporter gene assays were used to determine the transcriptional activity of LXRs in pancreatic beta cells. Cell viability and proliferation were analysed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DNA fluorometric, BrdU labelling and [(3)H]thymidine incorporation assays. Cell cycle distribution was investigated by flow cytometry analysis. Adenovirus-based RNA interference was used to knockdown LXRalpha, LXRbeta and p27 in MIN6 cells and mouse islets. RESULTS: We found that both Lxralpha (also known as Nr1h3) and Lxrbeta (also known as Nr1h2) were expressed and transactivated the LXR response element in HIT-T15 and MIN6 cells. Activation of LXRs dose-dependently inhibited pancreatic beta cell viability and proliferation. This was accompanied by beta cell cycle arrest at the G1 phase. Furthermore, LXR activation increased levels of the p27 protein by inhibiting its degradation. Knockdown of p27 reversed these effects of LXR activation on growth inhibition and cell cycle arrest. CONCLUSIONS/ INTERPRETATION: Our observations indicate that LXR activation inhibits pancreatic beta cell proliferation through cell cycle arrest. A well-known regulator of pancreatic beta cell cycle progression, p27, is upregulated and mediates the effects of LXRs on growth inhibition in beta cells. These observations suggest the involvement of aberrant activation of LXR in beta cell mass inadequacy, which is an important step in the development of type 2 diabetes.
Authors: Jong Bae Seo; Hyang Mi Moon; Woo Sik Kim; Yun Sok Lee; Hyun Woo Jeong; Eung Jae Yoo; Jungyeob Ham; Heonjoong Kang; Myoung-Gyu Park; Knut R Steffensen; Thomas M Stulnig; Jan-Ake Gustafsson; Sang Dai Park; Jae Bum Kim Journal: Mol Cell Biol Date: 2004-04 Impact factor: 4.272
Authors: D L Eizirik; D G Pipeleers; Z Ling; N Welsh; C Hellerström; A Andersson Journal: Proc Natl Acad Sci U S A Date: 1994-09-27 Impact factor: 11.205
Authors: Colin A Flaveny; Kristine Griffett; Bahaa El-Dien M El-Gendy; Melissa Kazantzis; Monideepa Sengupta; Antonio L Amelio; Arindam Chatterjee; John Walker; Laura A Solt; Theodore M Kamenecka; Thomas P Burris Journal: Cancer Cell Date: 2015-06-25 Impact factor: 31.743
Authors: Hannah J Welters; Abdelfattah El Ouaamari; Dan Kawamori; John Meyer; Jiang Hu; David M Smith; Rohit N Kulkarni Journal: Endocrinology Date: 2012-07-17 Impact factor: 4.736
Authors: Belinda K Cornes; Jennifer A Brody; Naghmeh Nikpoor; Alanna C Morrison; Huan Chu; Byung Soo Ahn; Shuai Wang; Marco Dauriz; Joshua I Barzilay; Josée Dupuis; Jose C Florez; Josef Coresh; Richard A Gibbs; W H Linda Kao; Ching-Ti Liu; Barbara McKnight; Donna Muzny; James S Pankow; Jeffrey G Reid; Charles C White; Andrew D Johnson; Tien Y Wong; Bruce M Psaty; Eric Boerwinkle; Jerome I Rotter; David S Siscovick; Robert Sladek; James B Meigs Journal: Circ Cardiovasc Genet Date: 2014-06
Authors: Karine H Hellemans; Jean-Claude Hannaert; Bart Denys; Knut R Steffensen; Cindy Raemdonck; Geert A Martens; Paul P Van Veldhoven; Jan-Ake Gustafsson; Daniel Pipeleers Journal: PLoS One Date: 2009-09-29 Impact factor: 3.240